NEW YORK (GenomeWeb News) – Promethera Biosciences today announced a collaboration with EMD Millipore to develop "an improved ready-to-use microfluidic perfusion liver assay."

Promethera added that it and EMD Millipore, a division of Germany's Merck KGaA, are receiving €900,000 ($1.2 million) from the Belgian Walloon Region Biocluster and the Massachusetts Life Sciences Center to support development of the assay, which is being designed so that "more robust studies in pre-clinical toxicity and drug metabolism" can be achieved.